Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Artiva Biotherapeutics, with four buy ratings, one strong buy, and one sell. The average 12-month price target is $39, substantially above the stock’s recent price of $6.50.
• Artiva shares fell 4% to $6.50 and remain well below their 52-week high of $14.53. The company reported a quarterly loss of $0.63 per share, matching estimates, while analysts expect a full-year loss of $2.62 per share.
• The clinical-stage biotechnology company is developing off-the-shelf natural killer cell therapies, led by AlloNK (AB-101), which is being tested with rituximab for autoimmune diseases including lupus and lupus nephritis.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $39.00.

Several equities analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $40.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. HC Wainwright reiterated a "buy" rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st.

Artiva Biotherapeutics Stock Down 4.0%

Shares of Artiva Biotherapeutics stock traded down $0.27 on Tuesday, hitting $6.50. 42,003 shares of the company's stock traded hands, compared to its average volume of 389,862. Artiva Biotherapeutics has a 52-week low of $2.71 and a 52-week high of $14.53. The firm's 50-day moving average is $9.75 and its 200 day moving average is $9.27. The stock has a market cap of $317.59 million, a P/E ratio of -1.97 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). Equities research analysts forecast that Artiva Biotherapeutics will post -2.62 EPS for the current year.

Insider Buying and Selling at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, COO Jennifer Bush sold 8,370 shares of the business's stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the transaction, the chief operating officer owned 366,159 shares in the company, valued at $2,504,527.56. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Subhashis Banerjee sold 8,222 shares of the business's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the completion of the sale, the insider directly owned 142,047 shares of the company's stock, valued at approximately $1,705,984.47. The trade was a 5.47% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders acquired 351,673 shares of company stock valued at $3,451,817 and sold 137,048 shares valued at $1,086,167. 1.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of ARTV. State of Wyoming bought a new stake in shares of Artiva Biotherapeutics in the second quarter valued at approximately $45,000. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics in the first quarter valued at about $131,000. Sanctuary Advisors LLC bought a new stake in shares of Artiva Biotherapeutics in the 1st quarter valued at approximately $139,000. Squarepoint Ops LLC bought a new stake in Artiva Biotherapeutics in the second quarter valued at $144,000. Finally, Simplify Asset Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the 1st quarter worth about $150,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc NASDAQ: ARTV is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva's lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.